Hoffmann-La Roche, Nutley, New Jersey.
SomaGenics, Inc, Santa Cruz, California.
Gastroenterology. 2014 Jan;146(1):63-6.e5. doi: 10.1053/j.gastro.2013.09.049. Epub 2013 Sep 27.
Short synthetic hairpin RNAs (sshRNAs) (SG220 and SG273) that target the internal ribosome entry site of the hepatitis C virus (HCV) were formulated into lipid nanoparticles and administered intravenously to HCV-infected urokinase plasminogen activator-severe combined immunodeficient mice with livers repopulated with human hepatocytes (humanized livers). Weekly administration of 2.5 mg/kg of each sshRNA for 2 weeks resulted in a maximal mean reduction in viral load of 2.5 log10 from baseline. The viral load remained reduced by more than 90% at 14 days after the last dose was given. The sshRNAs were well tolerated and did not significantly increase liver enzyme levels. These findings indicate the in vivo efficacy of a synthetic RNA inhibitor against the HCV genome in reducing HCV infection.
短合成发夹 RNA(sshRNA)(SG220 和 SG273)靶向丙型肝炎病毒(HCV)的内部核糖体进入位点,被制成脂质纳米颗粒,并静脉注射到用人类肝细胞(人源化肝脏)重新填充的携带 HCV 感染的尿激酶纤溶酶原激活物-严重联合免疫缺陷小鼠体内。每周给予每种 sshRNA2.5mg/kg,连续 2 周,可使病毒载量从基线最大平均降低 2.5log10。末次给药后 14 天,病毒载量仍降低超过 90%。这些 sshRNA 耐受性良好,并未显著增加肝酶水平。这些发现表明,针对 HCV 基因组的合成 RNA 抑制剂在降低 HCV 感染方面具有体内疗效。